# Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Study · id `cardio:ct-nct06274801` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06274801](<https://clinicaltrials.gov/study/NCT06274801>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06274801

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 330 participants.

## Technical summary

Registry record NCT06274801. Allocation not applicable; no masking; primary purpose treatment. Start 2024-09-03 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 330 participants (planned count; ClinicalTrials.gov record NCT06274801, source copy `cardio:ctgov-nct06274801-2026-10-13`, retrieved 2026-10-31)
- Started: 2024-09-03 (actual) (ClinicalTrials.gov record NCT06274801, source copy `cardio:ctgov-nct06274801-2026-10-13`, retrieved 2026-10-31)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06274801, source copy `cardio:ctgov-nct06274801-2026-10-13`, retrieved 2026-10-31)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06274801, source copy `cardio:ctgov-nct06274801-2026-10-13`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; Chile; Colombia; Czechia; Denmark; France; Germany; Greece; Ireland; Israel; Italy; Japan; Latvia; Lithuania; Mexico; Netherlands; Poland; Portugal; Romania; Saudi Arabia; Serbia; Singapore; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT06274801, source copy `cardio:ctgov-nct06274801-2026-10-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06274801-2026-10-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Seralutinib
- Intervention (Device): Gereic Dry Powder Inhaler
- Lead sponsor: Gossamer Bio USA, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 729f9508db702b3b4f81c7b00afd9ef63b8f294a24bfbb641c24a62cebd28743
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
